Transcription intermediary factor 1 (Tif1), a ubiquitous nuclear protein, is a regulator of transforming growth factor- (TGF-)/Smad signaling. Tif1 can function as an oncogene and as a tumor suppressor. In the present study, Tif1 levels were measured in the plasma of patients with breast cancer in order to investigate the association of Tif1 with overall survival (OS). The results indicated that Tif1 is an independent prognostic and predictive factor in breast cancer, and thus, a promising target protein for use in diagnostics and patient follow-up. Plasma levels of Tif1 were measured in samples obtained from 110 patients with operable breast cancer and in 110 healthy volunteers at the Breast Cancer Department of Yangpu Hospital between 2008 and 2016. The association between Tif1 levels and clinicopathologic parameters, and the OS in a follow-up period of 98 months was evaluated. The prognostic significance was assessed using the Kaplan-Meier method. The levels of Tif1 were significantly lower in patients with breast cancer compared with healthy controls. The average concentration of 18.40 ng/ml was used to discriminate between Tif1-positive (52) and Tif1-negative patients (58). Tif1-positive patients had a significantly improved OS compared with Tif1-negative patients. In the multivariate analysis, Tif1 was an independent predictor of a favorable OS in a prospective follow-up setting; thus, Tif1 plasma levels are an independent prognostic factor for patients with breast cancer. These findings support the potential of using measurements of Tif1 plasma levels to guide breast cancer therapy and monitoring. Further studies are required to validate Tif1 as an easily detectable, non-invasive prognostic biomarker for breast cancer.
[1]Tongji Univ, Sch Med, Yangpu Hosp, Dept Breast Surg, 450 Tengyue Rd, Shanghai 200090, Peoples R China;
[2]Fudan Univ, Sch Med, Huashan Hosp, Dept Gen Surg, Shanghai 200041, Peoples R China;
[3]Tongji Univ, Sch Med, Yangpu Hosp, Dept Cent Lab, 450 Tengyue Rd, Shanghai 200090, Peoples R China;
[4]Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Cardiol, Shanghai 200438, Peoples R China;
[5]Xi An Jiao Tong Univ, Hlth Sci Ctr, Sch Forens Sci, Dept Mol & Cellular Biol, Xian 710061, Shanxi, Peoples R China;
[6]Shanghai Univ Med & Hlth Sci, Dept Basic Med Sci, Shanghai 201318, Peoples R China;
[7]Univ Hosp Basel, Dept Internal Med, CH-4031 Basel, Switzerland
(8.0+极速模式)